Project Grant R44HL132172

This federal Project Grant award for $295,963 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the evaluation of platelet activities under hypoxic storage conditions for whole blood (WB) transfusion. The primary goal is to develop a modernized WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for improved...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, is providing $1,930,758 to Sylvatica Biotech Inc., a minority-owned small business, to develop innovative techniques for "enhanced supercooling" to enable extended preservation of clinical-scale human and porcine livers at high subzero temperatures. The goal is to achieve ice-free storage of...

This Project Grant award of $2,461,670.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of ErythroMer (EM), a dried, bio-inspired artificial red blood cell substitute, by Kalocyte Inc., a biotech startup. The project aims to optimize the lyophilization and reconstitution of EM to improve its oxygen binding and release properties, as well as evaluate its efficacy, pharmacokinetics, dosing, and compatibility with...

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

This Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $2,149,781 in funding to Rejuvenation Technologies Inc. (RTI) to develop advanced tools for the clinical translation of intravenously-infused RNA lipid nanoparticle (LNP) therapeutics. Specifically, the grant supports RTI's efforts to: Develop high-sensitivity analytical capabilities for their TERT mRNA LNP therapeutic drug product Conduct high-sensitivity...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $693,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant will fund the development and validation of a disposable microfluidic device capable of efficiently purifying platelets for pediatric and neonatal transfusions. The project aims to optimize the Controlled Incremental Filtration (CIF) technology to remove contaminants from platelet units while preserving...

This Small Business Innovation Research (SBIR) Phase II Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $998,527 to Insu Health Design Inc. to refine and optimize a temperature control and insulation system for storing and transporting temperature-sensitive medications, biologics, and other perishable components. The key innovation involves decoupling thermoelectric coolers from the cooled...

This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) will fund the development of a novel therapeutic delivery system called "Cargocytes" at the University of California, San Diego (UCSD). The $481,438 award aims to optimize the in vitro production, cryopreservation, and biobanking of Cargocytes, which are enucleated...

This $3,367,846 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Nour Heart Inc.'s development of the bioenergetic cardioprotective drug NOUREXAL (cyclocreatine phosphate) to increase the utilization of donor hearts for transplantation. The key objectives of this 2-year project are to: 1) produce GMP-grade NOUREXAL and determine its chemistry, manufacturing, and controls; 2) conduct...